Last updated: February 13, 2024
Sponsor: Changi General Hospital
Overall Status: Active - Recruiting
Phase
N/A
Condition
Vomiting
Ulcers
Hemorrhage
Treatment
Nexpowder
Clinical Study ID
NCT06269588
NBM-NP004
Ages 21-75 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Males or females aged over 21 to 75 years
- Patients with confirmed nonvariceal, upper gastrointestinal bleeding
- Patients who voluntarily agree to the clinical trial with informed consent
- Patients who willing and able to comply with the study protocol
Exclusion
Exclusion Criteria:
- Patients with an uncorrected coagulation disorder (PLT<50*109/L, INR>2)
- Patients who are known to be pregnant or in lactation
- Patients who have received another endoscopic treatment for the same part of the bodywithin the days preceding the study
- Patients for whom endoscopic treatment is prohibited due to comorbidity
- Patients for whom the 30-day follow-up period is impossible
- Patients who have participated within the past month in other related clinical trialsthat could affect the results of the study
- Other cases in which participation in the study is judged inappropriate by theinvestigators
Study Design
Total Participants: 24
Treatment Group(s): 1
Primary Treatment: Nexpowder
Phase:
Study Start date:
February 01, 2024
Estimated Completion Date:
December 31, 2024
Study Description
Connect with a study center
Changi General Hospital
Singapore, 529889
SingaporeActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.